{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:19:42Z","timestamp":1790371182556,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jid.2016.08.024","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T22:49:59Z","timestamp":1473720599000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Combining Type I Interferons and 5-Aza-2\u2032-Deoxycitidine to Improve Anti-Tumor Response against Melanoma"],"prefix":"10.1016","volume":"137","author":[{"given":"Valeria","family":"Lucarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Buccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Ziccheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Peschiaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sestili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Mattia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iole","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"D'Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"De Ninno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Gerardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mozetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Businaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5357-7773","authenticated-orcid":false,"given":"Fabrizio","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2016.08.024_bib1","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-14-1457","article-title":"Immuno-oncology combinations: a review of clinical experience and future prospects","volume":"20","author":"Antonia","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2015.12.003","article-title":"Microfluidics: a new tool for modeling cancer","volume":"2","author":"Boussommier-Calleja","year":"2016","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.jid.2016.08.024_bib3","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.4049\/jimmunol.162.10.5728","article-title":"Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation","volume":"162","author":"Bronte","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib4","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1039\/C2LC40887B","article-title":"Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment","volume":"13","author":"Businaro","year":"2013","journal-title":"Lab Chip"},{"key":"10.1016\/j.jid.2016.08.024_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CMR.0000000000000171","article-title":"Systemic immune changes associated with adjuvant interferon-\u00ce\u00b12b-therapy in stage III melanoma patients: failure at the effector phase?","volume":"25","author":"Chevolet","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2016.08.024_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jid.2016.08.024_bib8","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2016.08.024_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.25333","article-title":"Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy","volume":"128","author":"Dubrot","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2016.08.024_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/imt.13.108","article-title":"Epigenetics of melanoma: implications for immune-based therapies","volume":"5","author":"Fratta","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jid.2016.08.024_bib12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2016.08.024_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2230.2009.03207.x","article-title":"Perilesional treatment of metastatic melanoma with interferon-beta","volume":"34","author":"Fujimura","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2016.08.024_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.jid.2016.08.024_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A\u00a0prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jid.2016.08.024_bib16","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2016.08.024_bib18","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.29297","article-title":"Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients","volume":"136","author":"Jiang","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2016.08.024_bib19","doi-asserted-by":"crossref","first-page":"e1047584","DOI":"10.1080\/2162402X.2015.1047584","article-title":"Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages","volume":"4","author":"Kakizaki","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jid.2016.08.024_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1073\/pnas.022637199","article-title":"mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties","volume":"99","author":"Kang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2016.08.024_bib21","doi-asserted-by":"crossref","first-page":"14007","DOI":"10.1073\/pnas.96.24.14007","article-title":"Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells","volume":"96","author":"Karpf","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2016.08.024_bib22","first-page":"181","article-title":"Adjuvant therapy of melanoma","volume":"167","author":"Kaufman","year":"2015","journal-title":"Melanoma"},{"key":"10.1016\/j.jid.2016.08.024_bib23","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/labinvest.2014.87","article-title":"Melanoma epigenetics: novel mechanisms, markers, and medicines","volume":"94","author":"Lee","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.jid.2016.08.024_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/1744666X.2015.1002397","article-title":"Decitabine: a promising epi-immunotherapeutic agent in solid tumors","volume":"11","author":"Li","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-013-1506-7","article-title":"Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells","volume":"63","author":"Lim","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2016.08.024_bib26","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.4049\/jimmunol.1004163","article-title":"Type I IFNs control antigen retention and survival of CD8{alpha}+ dendritic cells afteruptake of tumor apoptotic cells leading to cross-priming","volume":"186","author":"Lorenzi","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/epi.15.66","article-title":"Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?","volume":"7","author":"Lowder","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.jid.2016.08.024_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/1547691X.2014.891677","article-title":"A\u00a0multidisciplinary study using in\u00a0vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells","volume":"11","author":"Mattei","year":"2014","journal-title":"J\u00a0Immunotoxicol"},{"key":"10.1016\/j.jid.2016.08.024_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2407-7-52","article-title":"Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta","volume":"7","author":"Micali","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2016.08.024_bib30","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2032-deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jid.2016.08.024_bib31","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib32","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.4049\/jimmunol.0900526","article-title":"APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions","volume":"184","author":"Pace","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.jid.2016.08.024_bib33","first-page":"51","article-title":"5-Aza-2\u2032-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends","volume":"7","author":"Pinto","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.jid.2016.08.024_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/PPO.0000000000000182","article-title":"Targeted therapies combined with immune checkpoint therapy","volume":"22","author":"Prieto","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.jid.2016.08.024_bib35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2015.02.012","article-title":"Immune checkpoint blockade and interferon-alpha in melanoma","volume":"42","author":"Rafique","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jid.2016.08.024_bib36","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2005.03.4074","article-title":"Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation","volume":"24","author":"Reu","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2016.08.024_bib37","article-title":"Interferon-\u03b2 gene transfer inhibits melanoma cells adhesion and migration","author":"Rossi","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jid.2016.08.024_bib38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00262-015-1776-3","article-title":"Improving cancer immunotherapy with DNA methyltransferase inhibitors","volume":"65","author":"Saleh","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2016.08.024_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib41","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2016.08.024_bib42","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.4049\/jimmunol.174.4.1932","article-title":"IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29","volume":"174","author":"Siren","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib43","first-page":"702","article-title":"Differing patterns of circulating regulatory T-cells and myeloid derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-\u03b1 or TLR-9 agonist and GM-CSF with peptide vaccination","volume":"35","author":"Tarhini","year":"2012","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.jid.2016.08.024_bib44","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17460441.2012.722618","article-title":"DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences","volume":"7","author":"Thomas","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.jid.2016.08.024_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc3486","article-title":"Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host","volume":"13","author":"Timp","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2016.08.024_bib46","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.4049\/jimmunol.174.7.4289","article-title":"IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression","volume":"174","author":"Tissari","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3181\/00379727-146-38196","article-title":"A\u00a0method for the large scale production of potent interferon preparations","volume":"146","author":"Tovey","year":"1974","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jid.2016.08.024_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jid.2016.08.024_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcancer.2012.02.003","article-title":"Melanoma-induced immunosuppression and its neutralization","volume":"22","author":"Umansky","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jid.2016.08.024_bib50","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.aad0779","article-title":"Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1","volume":"350","author":"Vacchelli","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jid.2016.08.024_bib51","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.18632\/oncotarget.2463","article-title":"Intratumoral administration of mRNA encoding a fusokine consisting of IFN-beta and the ectodomain of the TGF-beta receptor II potentiates antitumor immunity","volume":"5","author":"Van der Jeught","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2016.08.024_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nm0116-8","article-title":"Take two: combining immunotherapy with epigenetic drugs to tackle cancer","volume":"22","author":"Weintraub","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2016.08.024_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1309\/4EJ9KL7CGDENVVLE","article-title":"Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions","volume":"124","author":"Wenzel","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2016.08.024_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pharmthera.2015.01.003","article-title":"Immune checkpoint modulation: rational design of combination strategies","volume":"150","author":"Zamarin","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jid.2016.08.024_bib55","doi-asserted-by":"crossref","first-page":"19103","DOI":"10.1038\/srep19103","article-title":"3D tumor spheroid models for in\u00a0vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained","volume":"6","author":"Zanoni","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2016.08.024_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2016.08.024_bib57","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1078-0432.CCR-10-2672","article-title":"CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice","volume":"17","author":"Zoglmeier","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2016.08.024_bib58","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1158\/0008-5472.CAN-04-1987","article-title":"Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12\/CXCR4 signals","volume":"64","author":"Zou","year":"2004","journal-title":"Cancer Res"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16323685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X16323685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T02:25:20Z","timestamp":1692498320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X16323685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0022202X16323685"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2016.08.024","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining Type I Interferons and 5-Aza-2\u2032-Deoxycitidine to Improve Anti-Tumor Response against Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2016.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}